KNSA Nasdaq Pharmaceutical Preparations Financials FY2017βFY2025
Kiniksa Pharmaceuticals International, plc had $678M of revenue in fiscal 2025, up 60.1% on the year before.
Last close Β· Oct 23, 2026
$76.73
5.0%Hi! I read Kiniksa Pharmaceuticals International, plcβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+60.1%
Yes. Sales grew 60.1% last year.
Does it make a profit?
8.7%
A little. It keeps 8.7% of every sale as profit.
Does profit turn into cash?
20.1%
Yes. 20.1% of sales ends up as free cash.
How healthy are the accounts?
7 / 8
Solid. It passes 7 of 8 health tests.
How is the share priced?
84.3x
One share costs 84.3 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Kiniksa Pharmaceuticals International, plc did it, and the next one. Share prices often move a lot on those days.
Next results
October 27, 2026
Tuesday Β· tomorrow
| Date | Results for | Time | Source |
|---|---|---|---|
| Jul 28, 2026 | Period ended Jun 30, 2026 | Before the market opens | 8-K β |
| Apr 28, 2026 | Q1 '26 | Before the market opens | 8-K β |
| Jan 12, 2026 | Q4 '25 | After the market closes | 8-K β |
| Oct 28, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Jul 29, 2025 | Q2 '25 | Before the market opens | 8-K β |
| Apr 29, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Jan 13, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Oct 29, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Kiniksa Pharmaceuticals International, plc had $678M of revenue in fiscal 2025, up 60.1% on the year before. Its operating margin was 11.4%, up 22.2Β pts: of every 100 in sales, about 11 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Kiniksa Pharmaceuticals International, plc made $59.0M of net profit in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was $136M in fiscal 2025, 20.1% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders sold $47.8M of shares on the open market and bought none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$47.8M
8 insiders
Of sales under plans
99%
$47.5M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | Michael R MegnaChief Accounting Officer | Sold plan | 4,600 | $80.30 | $0.4M | Form 4 |
| Jul 29, 2026 | G Bradley ColeDirector | Sold | 3,673 | $81.43 | $0.3M | Form 4 |
| May 1, 2026 | Sanj K PatelChairman & CEO, Director | Sold plan | 48,565 | $54.02 | $2.6M | Form 4 |
| May 1, 2026 | John F. PaoliniChief Medical Officer | Sold plan | 58,424 | $53.71 | $3.1M | Form 4 |
| Apr 30, 2026 | Sanj K PatelChairman & CEO, Director | Sold plan | 2,141 | $54.01 | $0.1M | Form 4 |
| Apr 29, 2026 | Sanj K PatelChairman & CEO, Director | Sold plan | 22,544 | $54.01 | $1.2M | Form 4 |
| Apr 28, 2026 | Sanj K PatelChairman & CEO, Director | Sold plan | 483,654 | $51.86 | $25.1M | Form 4 |
| Apr 28, 2026 | Barry D QuartDirector | Sold plan | 13,099 | $50.10 | $0.7M | Form 4 |
| Apr 9, 2026 | Ross MoatChief Operating Officer | Sold plan | 1,703 | $46.69 | $0.1M | Form 4 |
| Apr 9, 2026 | Michael R MegnaChief Accounting Officer | Sold plan | 6,625 | $46.69 | $0.3M | Form 4 |
| Apr 6, 2026 | Barry D QuartDirector | Sold plan | 6,901 | $50.00 | $0.3M | Form 4 |
| Apr 6, 2026 | Sanj K PatelChairman & CEO, Director | Sold plan | 7,278 | $50.01 | $0.4M | Form 4 |
| Apr 6, 2026 | Ross MoatChief Operating Officer | Sold plan | 2,367 | $48.58 | $0.1M | Form 4 |
| Mar 9, 2026 | Mark RagosaChief Financial Officer | Sold plan | 36,722 | $45.92 | $1.7M | Form 4 |
| Mar 2, 2026 | John F. PaoliniChief Medical Officer | Sold plan | 40,000 | $44.82 | $1.8M | Form 4 |
| Feb 12, 2026 | Barry D QuartDirector | Sold plan | 2,690 | $45.00 | $0.1M | Form 4 |
| Feb 10, 2026 | Barry D QuartDirector | Sold plan | 110 | $45.00 | $0.0M | Form 4 |
| Feb 9, 2026 | Mark RagosaChief Financial Officer | Sold plan | 17,845 | $43.28 | $0.8M | Form 4 |
| Feb 4, 2026 | Barry D QuartDirector | Sold plan | 2,602 | $45.02 | $0.1M | Form 4 |
| Feb 3, 2026 | Barry D QuartDirector | Sold plan | 12,528 | $45.27 | $0.6M | Form 4 |
| Feb 2, 2026 | Barry D QuartDirector | Sold plan | 830 | $45.00 | $0.0M | Form 4 |
| Jan 8, 2026 | Mark RagosaChief Financial Officer | Sold plan | 12,000 | $41.89 | $0.5M | Form 4 |
| Dec 15, 2025 | Eben TessariChief Operating Officer | Sold plan | 12,048 | $41.56 | $0.5M | Form 4 |
| Dec 15, 2025 | Barry D QuartDirector | Sold plan | 20,129 | $41.51 | $0.8M | Form 4 |
| Dec 8, 2025 | Mark RagosaChief Financial Officer | Sold plan | 42,841 | $41.49 | $1.8M | Form 4 |
| Nov 26, 2025 | Eben TessariChief Operating Officer | Sold plan | 200 | $42.89 | $0.0M | Form 4 |
| Nov 17, 2025 | Eben TessariChief Operating Officer | Sold plan | 12,470 | $41.24 | $0.5M | Form 4 |
| Nov 12, 2025 | Mark RagosaChief Financial Officer | Sold plan | 19,900 | $40.94 | $0.8M | Form 4 |
| Oct 31, 2025 | John F. PaoliniChief Medical Officer | Sold plan | 82,542 | $37.14 | $3.1M | Form 4 |
| Oct 28, 2025 | Mark RagosaChief Financial Officer | Sold plan | 100 | $41.00 | $0.0M | Form 4 |
| Oct 22, 2025 | Sanj K PatelChairman & CEO, Director | Sold plan | 97,390 | $38.83 | $3.8M | Form 4 |
| Oct 21, 2025 | Sanj K PatelChairman & CEO, Director | Sold plan | 39,331 | $38.77 | $1.5M | Form 4 |
| Oct 20, 2025 | Michael R MegnaChief Accounting Officer | Sold plan | 50,490 | $38.87 | $2.0M | Form 4 |
| Oct 20, 2025 | Sanj K PatelChairman & CEO, Director | Sold plan | 121,248 | $38.90 | $4.7M | Form 4 |
| Oct 14, 2025 | Eben TessariChief Operating Officer | Sold plan | 12,368 | $37.67 | $0.5M | Form 4 |
| Sep 29, 2025 | Eben TessariChief Operating Officer | Sold plan | 42,000 | $38.33 | $1.6M | Form 4 |
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Kiniksa Pharmaceuticals International, plc can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $182M | $191M | $206M | $244M | $414M |
| Current ratio | 4.4x | 5.2x | 4.3x | 3.3x | 3.8x |
| Quick ratio | 4.3x | 4.7x | 3.9x | 3.0x | 3.4x |
| Total assets | $233M | $460M | $526M | $581M | $764M |
| Total liabilities | $47.8M | $63.5M | $87.5M | $142M | $196M |
| Shareholders' equity | $185M | $396M | $439M | $438M | $568M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Kiniksa Pharmaceuticals International, plc passes 7 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 6 | β / 6 | β / 6 | β / 6 | 6 / 8 | 3 / 8 | 4 / 8 | 7 / 8 |
| Accruals ratio | β30.9% | β12.0% | β1.2% | β8.2% | β10.9% | 51.3% | 0.2% | β12.4% | β11.8% |
| Altman Z'' | β16.81 | 8.17 | 4.59 | 6.53 | β5.64 | 6.00 | 4.64 | 2.40 | 5.08 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | β | β | β | β | $38.5M | $220M | $270M | $423M | $678M |
| Gross profit | β | β | β | β | $29.4M | $197M | $237M | $362M | $600M |
| Research and development | $56.4M | $86.6M | $135M | $112M | $99.3M | $65.5M | $76.1M | $112M | $96.9M |
| Operating income | β$65.4M | β$108M | β$170M | β$157M | β$157M | $9.8M | β$25.2M | β$45.6M | $77.2M |
| Pretax income | β$64.9M | β$103M | β$164M | β$156M | β$157M | $11.0M | β$16.7M | β$36.2M | $88.9M |
| Income tax | $0.0M | β$0.2M | β$2.0M | $5.2M | $1.4M | β$172M | β$30.7M | $7.0M | $29.9M |
| Net income | β$64.9M | β$103M | β$162M | β$161M | β$158M | $183M | $14.1M | β$43.2M | $59.0M |
| Diluted EPS | β$35.85 | β$3.49 | β$2.99 | β$2.61 | β$2.30 | $2.60 | $0.20 | β$0.60 | $0.75 |
| Diluted shares | 0.00B | 0.03B | 0.05B | 0.06B | 0.07B | 0.07B | 0.07B | 0.07B | 0.08B |
| Cash flow | |||||||||
| Cash from operations | β$50.2M | β$81.0M | β$158M | β$137M | β$126M | $5.8M | $13.3M | $25.7M | $138M |
| Capital expenditure | $0.1M | $5.3M | $3.2M | $0.3M | $0.4M | $0.1M | $0.1M | $0.3M | $1.6M |
| Free cash flow | β$50.3M | β$86.3M | β$162M | β$137M | β$127M | $5.7M | $13.2M | $25.4M | $136M |
| Depreciation and amortization | $0.0M | $0.3M | $2.1M | $2.4M | $2.4M | $2.4M | $2.3M | $1.7M | $1.6M |
| Stock-based compensation | $0.9M | $5.7M | $15.1M | $20.9M | $25.2M | $25.1M | $27.1M | $30.7M | $37.0M |
| Dividends paid | $0.0M | $0.0M | β | β | β | β | β | β | β |
| Dividends and buybacks | $0.0M | $0.0M | β | β | β | β | β | β | β |
| Balance sheet | |||||||||
| Cash and short-term investments | $45.6M | $307M | $233M | $323M | $182M | $191M | $206M | $244M | $414M |
| Current assets | $47.1M | $314M | $242M | $333M | $196M | $243M | $276M | $332M | $527M |
| Current liabilities | $17.4M | $42.6M | $27.8M | $31.8M | $44.8M | $47.1M | $63.7M | $101M | $139M |
| Inventory | β | β | β | $0.0M | $3.7M | $21.6M | $31.1M | $26.4M | $54.9M |
| Property and equipment, net | $0.1M | $6.4M | $6.4M | $4.1M | $2.8M | $1.7M | $0.7M | $0.7M | $1.9M |
| Intangible assets | β | β | β | $0.0M | $19.3M | $18.3M | $17.3M | $16.3M | $15.3M |
| Total assets | $47.5M | $322M | $255M | $349M | $233M | $460M | $526M | $581M | $764M |
| Total liabilities | $17.4M | $42.7M | $29.1M | $37.5M | $47.8M | $63.5M | $87.5M | $142M | $196M |
| Shareholders' equity | β$89.7M | $279M | $225M | $312M | $185M | $396M | $439M | $438M | $568M |
| Margins | |||||||||
| Gross margin | β | β | β | β | 76.4% | 89.6% | 87.6% | 85.6% | 88.5% |
| Operating margin | β | β | β | β | β406.4% | 4.4% | β9.3% | β10.8% | 11.4% |
| EBITDA margin | β | β | β | β | β400.3% | 5.5% | β8.5% | β10.4% | 11.6% |
| Net margin | β | β | β | β | β409.7% | 83.3% | 5.2% | β10.2% | 8.7% |
| FCF margin | β | β | β | β | β328.7% | 2.6% | 4.9% | 6.0% | 20.1% |
| Returns | |||||||||
| Return on capital employed | β217.6% | β38.7% | β75.0% | β49.5% | β83.3% | 2.4% | β5.4% | β9.5% | 12.4% |
| Return on equity | β | β108.9% | β64.1% | β60.1% | β63.6% | 63.1% | 3.4% | β9.8% | 11.7% |
| Return on assets | β136.6% | β55.9% | β56.2% | β53.4% | β54.2% | 53.0% | 2.9% | β7.8% | 8.8% |
| Return on tangible equity | β | β37.0% | β71.8% | β51.7% | β95.3% | 48.5% | 3.3% | β10.2% | 10.7% |
| Growth | |||||||||
| Revenue growth | β | β | β | β | β | 471.2% | 22.7% | 56.6% | 60.1% |
| Net income growth | β | β | β | β | β | β | β92.3% | β406.7% | β |
| EPS growth | β | β | β | β | β | β | β92.3% | β400.0% | β |
| FCF growth | β | β | β | β | β | β | 131.0% | 92.9% | 436.8% |
| Share count change | β | 1,532.6% | 82.9% | 14.4% | 10.9% | 2.7% | 2.1% | β0.7% | 10.6% |
| Financial health | |||||||||
| Current ratio | 2.7x | 7.4x | 8.7x | 10.5x | 4.4x | 5.2x | 4.3x | 3.3x | 3.8x |
| Quick ratio | 2.7x | 7.4x | 8.7x | 10.5x | 4.3x | 4.7x | 3.9x | 3.0x | 3.4x |
| Capital allocation | |||||||||
| Capex / revenue | β | β | β | β | 1.1% | 0.0% | 0.0% | 0.1% | 0.2% |
| Stock comp / revenue | β | β | β | β | 65.3% | 11.4% | 10.0% | 7.3% | 5.5% |
| Quality scores | |||||||||
| Piotroski F-score | β | β | β | β | β | 6.0 | 3.0 | 4.0 | 7.0 |
| Altman Z'' | β16.8 | 8.2 | 4.6 | 6.5 | β5.6 | 6.0 | 4.6 | 2.4 | 5.1 |
| Accruals ratio | β30.9% | β12.0% | β1.2% | β8.2% | β10.9% | 51.3% | 0.2% | β12.4% | β11.8% |
Source: SEC EDGAR XBRL filings (CIK 0001730430). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
